Skip to main content
. 2017 Oct 9;8(59):100021–100033. doi: 10.18632/oncotarget.21754

Figure 1. Glipizide sensitizes TRAIL-mediated apoptosis in lung adenocarcinomacells.

Figure 1

A549, HCC-15 and Calu-3 cells were pre-incubated with glipizide at different doses (0, 25, 50, and 100 μM) for 12 h and exposed to TRAIL protein 200 ng/ml for 2 h. (A and E) Cell morphology photographed using light microscope in A549 and Calu-3 Cells (×100); (B and G) Cell viability was measured with crystal violet assay in A549 andHCC-15 Cells; (C and H) Bar graph indicating the average density of crystal violet in A549 andHCC-15 Cells; (D and F) Cell viability was measured with trypan blue dye exclusion assays in A549 and Calu-3 Cells. ** p<0.01, *** p < 0.001: represent significant differences between control and each treatment group; Gli: Glipizide; TRAIL: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand.